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Cardiomyopathies: Therapeutics Based on Molecular Phenotype
Houman Ashrafian, MA, MRCP, Hugh Watkins, MD, PHD
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The enduring subdivision of cardiomyopathies into hypertrophic (HCM), dilated (DCM), and restrictive (RCM) cate-
gories reflects the emphasis of traditional classifications on morphology. Rapid advances in the genetic interro-
gation of these disorders have redefined their taxonomy and revealed potential conflicts between the old and
new classifications. Hypertrophic cardiomyopathy has been redefined as a disease of perturbed sarcomere func-
tion. Dilated cardiomyopathy is a disease that results from more varied perturbations, including, but not limited
to, defects of the cytoskeleton. Positional cloning and candidate gene approaches have been successful in iden-
tifying 40 disease loci, many of which have led to disease genes in HCM, DCM, RCM, and arrhythmogenic right
ventricular cardiomyopathy. These findings provide mechanistic insights, permit genetic screening, and to a lim-
ited extent, facilitate prognostication. Although single gene analyses rapidly focus down to the underlying mech-
anistic pathways, they do not take account of all relevant variation in the human genome. Correspondingly, ad-
vances in genomics, through microarrays, have facilitated characterization of these broader downstream
elements. As well as refining the taxonomic reclassification of cardiomyopathies, these genomic approaches,
coupled with functional studies, have identified novel potential therapeutic targets, such as cardiac energet-
ics, calcium handling, and apoptosis. We review the successes and pitfalls of genetic and genomic ap-
proaches to cardiomyopathy and their impact on current and future clinical care. (J Am Coll Cardiol 2007;
49:1251–64) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.10.073a
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one hundred fifty years since Mendel’s breeding experi-
ents, 50 years since the discovery of the structure of
eoxyribonucleic acid by Watson and Crick, and 5 years
rom the publication of the human genome draft, the
nprecedented pace of technologic progress has inspired
we and built up expectations that genetics and genomics
ill provide radical insights into disease. In inherited single
ene disorders, and in the relatively simple somatic genetics
f cancer, important mechanistic insights have been af-
orded, leading to improved diagnosis, screening, and prog-
osis. Genomic tools have honed stratification (e.g., by the
se of array technology in leukemia, breast cancer, mela-
oma) (1), and some therapeutics have been personalized
e.g., gefitinib in lung cancer [2]).
Cardiovascular disease is the leading cause of illness and
eath worldwide, with an estimated 1 million deaths annu-
rom the Department of Cardiovascular Medicine, John Radcliffe Hospital, Oxford,
nited Kingdom. Drs. Ashrafian and Watkins have received funding from the British
eart Foundation and the Wellcome Trust Functional Genomics Initiative. Cardio-
ascular Genomic Medicine series is edited by Geoffrey S. Ginsburg, MD, PhD.u
Manuscript received July 17, 2006; revised manuscript received October 24, 2006,
ccepted October 30, 2006.lly in the U.S. alone (40% of all-cause mortality).
pecifically, heart failure has a prevalence of 2% with an
nnual U.S. mortality of 300,000 and an annual cost of
17 billion. Most of the burden of cardiovascular disease has
omplex genetic and environmental origins and is only now
ecoming amenable to large-scale genetic analyses. Prelim-
nary findings are beginning to indicate the potential of
enetic dissection of common cardiovascular diseases (e.g.,
he identification of ALOX5AP mutations that modify
eukotriene B4 metabolism and are associated with myocar-
ial infarction and stroke) (3). But progress sufficient to
lready be clinically relevant has largely been confined to the
ess common monogenic forms of the various cardiovascular
athologies: contributions to lipid disorders (e.g., low-
ensity lipoprotein receptor mutations in familial hypercho-
esterolemia), hypertension (e.g., epithelial Na channel,
NaC, mutations in Liddle’s syndrome), cardiomyopathies,
nd channelopathies. In the present review, we highlight
he successes and pitfalls of genomic approaches to
isease-gene, susceptibility-gene, and pathway discovery
sing the cardiomyopathies as our model. The cardiomy-
pathies were the first primary cardiac disorders to be
nderstood at the molecular level, offering the potential
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gies not only for patients with
cardiomyopathies but also for
heart failure in general.
Genetics: Insights Into
the Classification and
Mechanisms of Disease
Cardiomyopathies are a diverse
and important group of heart mus-
cle diseases which through mechan-
ical and/or electrical dysfunction of-
ten lead to cardiovascular morbidity
and mortality. The traditional clas-
sification of cardiomyopathies,
guided by the observations of mor-
bid anatomists, as befitted their then
state-of-the art technology, were re-
stricted to morphologic-clinical cor-
relations. Those classifications have
not, however, always corresponded
neatly to the rapidly emerging ge-
netic insights; accordingly a reclassi-
fication has been proposed, predi-
ated on the findings in mendelian single-gene disorders. As
escribed subsequently, a genetically guided classification is far
rom complete. Nevertheless, when grounded in the indelible
enetic etiology of disease and complemented by the wealth of
linical and accumulating genomic experience, such an approach
ermits multiple iterations in the classification of cardiomyopa-
hies, which will evolve into the most useful and accurate taxon-
my (4).
Linkage studies, the classic approach to identifying
ingle-gene disorders, start with the identification of ex-
ended families exhibiting a disorder, ideally with mendelian
nheritance. The identification of abundant markers, such as
icrosatellites and single-nucleotide polymorphisms
SNPs), interspersed with functional genes has allowed
tatistical analysis of the inheritance of those markers and
isease phenotypes within families. Knowing the position of
hose markers and determining which of them cosegregate
i.e., are “linked”) with the disease in families has led to the
positional” mapping of1,600 human disease loci. However,
he gene vicinity (locus) is only identified to between 100 and
,000 kbp, and there may be hundreds of genes within the
egion. Narrowing down to the culprit depends on short-listing
andidate genes based on mechanistic knowledge of disease
athogenesis and/or examining each and every gene in turn
ntil disease-causing variants are found.
ypertrophic Cardiomyopathy (HCM):
Disease of Sarcomeres and Energy
ypertrophic cardiomyopathy is the archetypal example of
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
ARVC  arrhythmogenic
right ventricular
cardiomyopathy
DCM  dilated
cardiomyopathy
HCM  hypertrophic
cardiomyopathy
LVAD  left ventricular
assist device
LVH  left ventricular
hypertrophy
MHC  myosin heavy chain
MLP  muscle LIM protein
RCM  restrictive
cardiomyopathy
SCD  sudden cardiac
death
SNP  single-nucleotide
polymorphismositional cloning in cardiovascular disease. Its description cn 1958 by British pathologist Donald Teare as a rare
tumour of the heart” based on asymmetric left ventricular
ypertrophy (LVH) and outflow tract obstruction (5) has
eded to its recognition as a heterogeneous, relatively
ommon disorder with a prevalence of 1:500 (6). Its
ignificance is underscored by its identification as the most
ommon cause of sudden cardiac death (SCD) in young
dults and in athletes (7).
In 1989, HCM was mapped to chromosome 14 in a
rench-Canadian pedigree with autosomal dominant dis-
ase, and, thereafter, mutations in cardiac -myosin heavy
hain (MHC) were shown to cause HCM (8,9). Subsequent
tudies have revealed that HCM is more complex than
nticipated, exhibiting genetic (multiple disease gene) and
llelic (multiple mutation) heterogeneity, with as many as 9
arcomeric genes and 400, predominantly missense, mu-
ations described (10) (Table 1). That led to the proposition
hat HCM is a disease of the sarcomere (11,12). Despite
hat success, comprehensive screening detects sarcomeric
utations in only60% of HCM families. Some mutations
ay have been missed by the indirect sequencing techniques
sed, but failure to find a mutation in such a significant
roportion clearly indicates that other novel HCM genes
re yet to be found. The identification of missense muta-
ions in muscle LIM protein (MLP) represents an example
f such novel HCM disease genes (13). Muscle LIM
rotein has an increasingly large repertoire of functions,
ncluding cellular differentiation, growth, and cytoskeletal
rganization. Such nonsarcomeric disease genes will reveal
dditional hits in the HCM pathogenic pathway and will
rive an improvement in our understanding of disease.
The insight that HCM arises from perturbations of the
arcomere provided unheralded opportunities to explore its
CM and Phenotypically Similar Syndromes:enes, Chromosomal Loci, Gene Pro uct, andode of Inheritance
Table 1
HCM and Phenotypically Similar Syndromes:
Genes, Chromosomal Loci, Gene Product, and
Mode of Inheritance
Chromosomal
Locus Gene Protein Inheritance
1q32 TNNT2 Cardiac troponin T AD
2q31 TTN Titin AD
3p21 MYL3 Ventricular essential myosin light
chain
AD & AR(?)
7q36 PRKAG2 AMPK-2 subunit AD
11p11 MYBPC3 Cardiac myosin-binding protein C AD
11p15 CSRP3 Cardiac muscle LIM protein AD
12q23–q24 MYL2 Ventricular regulatory myosin
light chain
AD
14q12 MYH7 -myosin heavy chain AD
15q14 ACTC -cardiac actin AD
15q22 TPM1 -tropomyosin AD
19q13 TNN13 Cardiac troponin 1 AD
Xq24 LAMP2 Lysosome-associated membrane
protein 2
X-linked
or citations to original references, see http://genetics.med.harvard.edu/seidman/cg3/
ndex.html.
AMPK  adenosine monophosphate-activated protein kinase; HCM  hypertrophic
ardiomyopathy.
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March 27, 2007:1251–64 Genomics of Cardiomyopathyathogenesis. The genetic findings led to the suggestion
hat mutated, putatively poorly functioning, sarcomeres may
mpair myocyte function, triggering adaptive mechanisms
esulting in compensatory LVH (14). Although intuitively
ppealing, in vitro assays of sarcomeric function demon-
trated divergent results: Although a few HCM mutant
roteins reduced maximum force generation, the majority
nhanced contractility (15). The “compensatory hypertro-
hy hypothesis” for HCM was accordingly refuted. These
tudies underscore the importance of validation of all
enetic findings with translational genetic, molecular, and
linical studies.
Because no mechanistic knowledge of disease patho-
enesis is necessary for successful genetic mapping, it has
he merit of identifying unexpected genes and signaling
athways. Correspondingly, further genetic assessment iden-
ified mutations in the PRKAG2 gene encoding the -2
ubunit of adenosine monophosphate-activated protein kinase
AMPK) in a syndrome resemblingHCM in conjunction with
olff-Parkinson-White syndrome and progressive conduction
isease (16). Adenosine monophosphate-activated protein
inase is a cellular energy sensor whose activation by
nergetic stress is one of the cell’s key mechanisms for
nergy regulation. Furthermore, disorders causing defects in
Figure 1 HCM: A Disease of Energy Deficiency
As indicated in red, the phenotype of hypertrophic cardiomyopathy (HCM) can arise
production (e.g., from poorly functioning mitochondria), inadequate metabolic subs
tectural defects as exemplified by muscle LIM protein (MLP) mutations; or 3) aber
mutations). The final common path for these diverse defects is energy deficiency a
phate; ATP  adenosine triphospate; Cr  creatine; FAM  fatty acid metabolismardiac energy metabolism, such as mitochondrial mutations
nd Friedreich’s ataxia, exhibit HCM-like features. These
bservations gave weight to an emerging hypothesis, based
n functional studies of mutant contractile proteins, that the
nifying defect in HCM is energy deficiency. Sarcomere
utations are a potent source of energy deficiency through
nefficient or profligate energy use (e.g., troponin T muta-
ions) (17,18). The hypothesis has been supported by
arious clinical studies (19) and is increasingly accepted
20), extending the “disease of the sarcomere” concept to
ne of energy deficiency (Fig. 1). More recently, it has been
ecognized that even the missense mutations in MLP,
hich are only distantly related to sarcomeric function, can
e integrated into this energy deficiency concept. Muscle
IM protein is critical to cytoskeletal architecture; the
LP-null mouse heart is a model of cytoarchitectural
isorganization. It appears that a failure of energy transfer
rom its source of generation (mitochondria) to its site of use
sarcomeres) results in subcellular energy deficiency, con-
ributing to energetic and contractile dysfunction (21). The
ombination of genetic linkage, functional genomics, and
ranslational studies in HCM thus promises a rational
pproach to therapy, extending existing insights by identi-
: 1) excessive energy use (e.g., by aberrant sarcomeres); 2) inadequate energy
, or a failure to transfer energy across cellular compartments owing to cytoarchi-
gnaling of energy deficiency (e.g., with AMP-activated protein kinase [AMPK]
suing hypertrophy. ADP  adenosine diphosphate; AMP  adenosine monophos-from
trates
rant si
nd en
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lues to disease pathways and therapeutic targets.
ilated Cardiomyopathy (DCM):
he End Result of Diverse Pathways
nsights into DCM, a common disorder of cardiac chamber
ilatation and systolic impairment, have developed in an
nalogous, albeit circuitous, manner. Whereas HCM is
rincipally a genetic disorder, the DCM phenotype can be
aused by ischemia, infection, hypertension, pregnancy,
lcohol, autoimmune disease, and of course genetic inheri-
ance. Traditionally, geneticists attempt to purify a genetic
ubstrate by stratifying patients; however, apart from a
amily history, in DCM cases there is often little to
istinguish the genetic and acquired variants. Nevertheless,
concerted effort to validate pedigrees (using echocardio-
rapic screening for asymptomatic left ventricular enlarge-
ent) has confirmed that 20% to 50% of idiopathic DCM
ases have an inherited disease (22).
Linkage mapping to identify novel disease genes in DCM
as been difficult, because of the underlying problems of
ultiple disease phenocopies, incomplete and often age-
elated penetrance, and poor survival in affected pedigrees.
herefore, a number of loci have been mapped which have
et to reveal the underlying disease gene (Table 2). Instead,
CM gene discovery was initially driven by candidate gene
ypotheses. For example, it had been noted that DCM was
feature of Duchenne’s (80%) and Becker’s (10%)
uscular dystrophies caused by mutations in the dystrophin
ene and that some DCM cases segregated as X-linked
raits without myopathy. It was hypothesized that dystro-
hin and other cytoskeletal proteins might underlie some
ases of DCM, a hypothesis that was ultimately confirmed
23). This appreciation of DCM as a disorder of impaired
ytoskeletal force transmission and mechanotransduction
ed initially to DCM’s sobriquet of a disorder of the
ytoskeleton and to identification of related genes, such as
ardiac actin (24).
Further studies in families with DCM (sometimes with
ssociated features such as sensorineural deafness, conduc-
ion defects, or skeletal myopathy) subsequently identified
ore diverse DCM genes (25) (Table 2) . Of note, specific
CM mutations have been identified in 6 sarcomeric genes
reviously known to cause HCM. The DCM and HCM
utations in the same genes have fundamentally opposite
roperties, and each causes one or another cardiomyopathy
ithout apparent overlap (26). Moreover, mutations in the
uclear envelope intermediate filament proteins, lamins
/C, identified in Emery-Dreifuss muscular dystrophy with
CM, modify nuclear signaling. Taken together, these
bservations show that diminished force generation and
ransmission and altered mechanotransduction and myocyte
ignaling can all cause DCM. Abnormalities of “down-
tream” pathways can also produce the same phenotype;
hese include mitochondrial mutations that compromise 1nergy production and mutations in adenosine triphospahte
ATP)-sensitive potassium channels and phospholamban
hat modify calcium signaling. Genetic insights in DCM
ave informed our understanding of its pathogenesis, much
s they have for HCM, but have revealed a more diverse set
f underlying processes (27).
Other cardiomyopathies are earlier in their nosology.
rrhythmogenic right ventricular cardiomyopathy (ARVC)
s an uncommon disorder of cardiac muscle exhibiting
rogressive fibrofatty replacement of the right and, variably,
eft ventricle. Ventricular dilatation, arrhythmia, and SCD
re key manifestations of ARVC. Positional cloning has
dentified 11 loci, of which the gene has been identified
t 5, including plakoglobin, desmoplakin, plakophilin-2,
esmoglein-2, and desmocollin-2, each encoding a compo-
ent of the desmosome junction complex. Desmosomes
nchor intermediate filaments to the cytoplasmic mem-
ranes in adjoining cells, thereby conferring mechanical
trength. The consequence of desmosomal dysfunction is
yocyte detachment and death, with ensuing inflammation
nd fibrofatty replacement providing the substrate for ar-
hythmia and ventricular dysfunction. Thus far, these ge-
etic findings provide the taxonomic insight that ARVC
ppears to be a specific phenotypic response to disruption of
esmosome function (28,29).
s Genetic Screening for
iagnosis and Prognosis Feasible?
t is apparent that although genetic studies have yielded and
ill continue to yield invaluable biologic clues, they have
lso uncovered considerable unanticipated complexity. Can
he identified genes be used to identify disease carriers?
creening. A key finding exposed by genetic analyses is
hat penetrance (the likelihood that a mutation carrier will
ave overt disease) is incomplete in all forms of HCM even
n adulthood and can be as low as 50% for some mutations
12,15). A consequence of this is that familial disease was
reviously under-recognized. Indeed, 90% of patients pre-
enting with HCM in adult life will have familial disease
nherited from one or the other parent. A related aspect of
CM’s complexity is its profound phenotypic heterogene-
ty, e.g., in relation to the distribution as well as extent of
ypertrophy, the presence or absence of a gradient, or the
xtent of ECG abnormalities. Although history, clinical
xamination, and electrocardiography may contribute to the
iagnosis of HCM, the main tool for diagnosis remains
chocardiographic assessment of LVH. However, echocar-
iography is not without its challenges; apart from having to
xclude other conditions exhibiting LVH, the distinction
etween pathologic hypertrophy (hypertensive hypertro-
hy), physiologic hypertrophy (athlete’s heart), and HCM
as proved to be especially demanding (30). Further, there
re difficulties in defining the period for which screening is
ecessary. Conventionally, this might begin at 10 years to
2 years of age and continue annually into adulthood (21
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March 27, 2007:1251–64 Genomics of Cardiomyopathyears of age). However, even though the majority of
utation carriers develop HCM by the time of physical
aturity (18 years of age), HCMmay first manifest either
CM- and ARVC-Causing Genes, Chromosomal Loci, Gene Product,ode of Inheritance, and Associated Distinguishing Phenotypes
Table 2 DCM- and ARVC-Causing Genes, Chromosomal Loci, GeMode of Inheritance, and Associated Distinguishing Ph
Chromosomal Locus Gene Protein
DCM autosomal dominant inheritance
1p1–q21 LMNA Lamins A & C
1p1–q21 LMNA Lamins A & C
1q32 TNNT2 Cardiac troponin
2q14–q22 ? ?
2q31 TTN Titin
2q35 DES Desmin
3p22–p25 ? ?
5q33 SGCD -sarcoglycan
6q12–q16 ? ?
6q22 PLN Phospholamban
6q23 ? ?
6q23–q24 EYA4 Eya4
9q13–q22 ? ?
9q22–q31 ? ?
10q22–q23 VCL Metavinculin
11p11 MYBPC3 Cardiac myosin-
protein C
12p12.1 ABCC9 ATP-sensitive K
channel
14q12 MYH7 -myosin heavy
15q14 ACTC -cardiac actin
15q22 TPM1 -tropomyosin
DCM autosomal recessive inheritance
4q12 SCGB -sarcoglycan
6p24 DSP Desmoplakin
DCM X-linked inheritance
Xp21 DMD Dystrophin
Xq28 G4.5 Tafazzin
Xq28 EMD Emerin
ARVC autosomal dominant inheritance
1q42–q43 RyR2 Cardiac ryanodi
receptor
2q32 ? ?
3p23 ? ?
6p24 DSP Desmoplakin
10p12–14 ? ?
10q22 ? ?
12p11 PkP2 Plakophilin-2
14q12–22 ? ?
14q23–24 ? ?
ARVC autosomal recessive inheritance
17q21 JUP Plakoglobin
18q12.1-12.2 DSG2 Desmoglein-2
18q12.1 DSC2 Desmocollin-2
RVC  arrhythmogenic right ventricular cardiomyopathy; DCM  dilated cardiomyopathy.n childhood or, alarmingly, in later adulthood (10). Late anset is well recognized for MYBPC3 mutations but is also
een with other mutations. The corollary of these findings is
hat patients can develop LVH, and with it a risk for SCD,
roduct,
ypes
Inheritance Phenotype/Associated Abnormality
AD DCM  conduction system disease
AD DCM  skeletal myopathy (AD Emery-Dreifuss
or limb-girdle muscular dystrophies) 
conduction-system disease
AD Pure DCM
AD DCM  conduction system disease
AD Pure DCM
AD Pure DCM
AD DCM  conduction system disease
AD Pure DCM
AD Pure DCM
AD Pure DCM
AD DCM  skeletal myopathy (limb-girdle muscular
dystrophy)  conduction-system disease
AD DCM  sensorineural deafness
AD Pure DCM
AD Pure DCM
AD Pure DCM
g AD Pure DCM
AD Pure DCM
AD Pure DCM
AD Pure DCM
AD Pure DCM
AR Limb-girdle muscular dystrophy  severe DCM
AR DCM  woolly hair and keratoderma
X-linked X-linked DCM, Duchenne & Becker muscular
dystrophy
X-linked X-linked infantile DCM, Barth syndrome,
hypertrophic DCM, endocardial fibroelastosis,
and left ventricular noncompaction
X-linked X-linked Emery-Dreifuss muscular dystrophy
AD ARVD2, catecholaminergic polymorphic
ventricular tachycardia
AD ARVD4
AD ARVD5
AD ARVD8
AD ARVD6
AD ARVD7, skeletal myopathy
AD ARVD9
AD ARVD3
AD ARVD1
AR Naxos disease, palmoplantar keratosis,
woolly hair
AD ARVD10
AD ARVD11ne P
enot
T
bindin
chain
nefter the age of 21 years, and although a pragmatic age
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Genomics of Cardiomyopathy March 27, 2007:1251–64ut-off will identify most patients, it will have a significant
alse-negative rate. In short, at any given time point, any
egree of left ventricular wall thickness, even normal thick-
ess, may be consistent with HCM and increased cardiac
isk (4).
Conversely, other cardiac disorders may present with
chocardiographic features indistinguishable from HCM.
ermed phenocopies, those conditions do not, in many
ases, carry the same prognostic implications as HCM.
hey are well recognized in the pediatric setting and include
oonan syndrome resulting from PTPN11, KRAS, and
OS mutations, mitochondrial myopathies, glycogen stor-
ge diseases, and infiltrative myopathies. Distinguishing
hese conditions from HCM is often important and difficult.
To contend with this incomplete age-related penetrance
nd to increase ascertainment in the “at-risk” population
sing clinical tools, either echocardiographic screening
ould need to continue indefinitely (at great financial and
motional cost), or a more sensitive form of echocardiogra-
hy (e.g., tissue Doppler imaging) would have to be vali-
ated that would identify patients with HCM but no overt
VH (31). It is also apparent that with respect to pheno-
opies, even these advanced techniques may be inadequate
o diagnose or exclude HCM. With the identification of
utations in HCM, DCM, and ARVC, optimism has
rown for affordable, rapid, sensitive, and specific genetic
esting. For modest costs ($2,000 in the U.S., less in
urope) and 10 ml blood, patients or their physicians can
ow test directly for HCM mutations (10). Although this is
ne of the first direct clinical applications of genetics in
ardiac disease, and has considerable utility in the right
etting, it is not without limitations. The question remains:
n what contexts can genetic screening be practicable?
OPULATION SCREENING. Although research studies have
ssessed the number of HCM gene carriers with increased
eft ventricular wall thickness in the community (32), this
ould not be feasible for routine clinical surveillance. First,
he “pick-up rate” for mutations is 50% to 70% at best;
herefore, a large number of false negatives would be
enerated in community screening. Secondly the effort to
creen thousands of kilo-base pairs, even for only the 8
arcomeric HCM genes, remains a significant exercise even
ith state-of-the art technology. One solution would be to
estrict screening to MYH7 and MYBPC3, which account
or 80% of HCM mutations identified (33), but the false-
egative rate would be higher and important classes of
utations (e.g., in cardiac troponin T) would be missed.
mportantly, similar arguments apply to patients suspected
f HCM; if the clinical likelihood is low, then the yield
rom genetic screening is too low for the analysis to be
ffordable. Moreover, a negative screen cannot rule out
CM.
ASCADE SCREENING. In contrast, genetic screening is
aluable in evaluation of the families of index patients
nown to have HCM. There is a reasonable probability t50% to 70%) that presenting patients will have their
utation identified, if the proband mutation is identified
he rest of the family can be definitively and rapidly screened
at much lower cost). The Bayesian principle that in an
utosomal dominant condition, parents, siblings, or off-
pring have a 50% pretest probability of being positive for a
nown mutation (rather than the 1 in 500 to 1 in 300
hance of being positive for any gene mutation in the
opulation) makes genetic testing within families highly
ewarding. This “cascade” screening of potentially affected
amily members avoids the problems of incomplete age-
elated penetrance and phenocopies. Unaffected individuals
an be conclusively reassured and discharged, and the
ffected individuals within the extended family can be
dentified. In contrast, family screening with clinical tools
ends to be ineffective because of false-negative results that
erminate the cascade inappropriately. Cascade genetic
creening of HCM families is already useful and practicable
nd provides a mandate for routine genotyping of newly
iagnosed patients who have relatives at risk. Particular
enefits apply in those families where clinical diagnosis is
ore difficult owing to incomplete penetrance, not least in
roponin T mutations where risk of SCD is often high (see
ubsequent text).
Although genetic screening is not practicable for the
ajority of patients with DCM, assessment of patients with
CM associated with specific clinical features may be more
ewarding. Genetic screening of patients with DCM as part
f a skeletal myopathy syndrome, or with revealing features
uch as conduction defects, may be immediately clinically
pplicable. Up to 30% of the latter patients have been
eported to carry lamins A/C mutations and therefore
hould be considered for screening. Similarly, the mutation
ield in ARVC may soon be adequate for clinical utility. In
ll cases, negative genetic screens remain common and
annot rule out disease, but the value of a positive result for
ascade screening in familial assessment is considerable.
rognosis. While a number of clinical parameters are used
o stratify HCM patients, individually they are of limited
alue. In HCM the most powerful predictor of sudden
eath is previous cardiac arrest (7-year mortality of 67%).
ven a personal history of syncope or a family history of
CD has positive predictive value (PPV) and negative
redictive value (NPV) of 25% and 85%, respectively.
ommonly used HCM risk factors, such as nonsustained
entricular tachycardia on Holter monitoring, hypotension
n upright exercise, or severe LVH30 mm, have low PPV
34). Over-reliance on risk factors with reasonable NPV but
oor PPV mandates a need to better stratify patients, if only
o reduce indiscriminate cardioverter-defibrillator implanta-
ion (35). Combining risk factors may allow global risk
ssessment with a better PPV; that approach, however, has
ot yet been prospectively evaluated.
An attractive alternative might be to institute genetic
rognostication. However, the role of mutation analysis in
he assessment of prognosis remains unclear. The first
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March 27, 2007:1251–64 Genomics of Cardiomyopathybstacle is that all cardiomyopathy mutations are individu-
lly rare and many families will turn out to have a “private”
utation not previously described. Therefore, it will take
ime to build databases with sufficient cumulative mutation-
pecific data to give a reliable readout. The second obstacle
s confounding through ascertainment bias. Mutations that
onsistently produce severe disease will be over-represented
n families studied in specialist centers. Existing genotype-
henotype studies based mainly on large families ascertained
n referral centers are therefore enriched for a subset of more
ighly deleterious genes; early studies tended to overesti-
ate the prevalence of such variants. In contrast, most
utations produce a spectrum of disease severity, influenced
y modifier genes and/or environmental factors. To reach a
eferral center, probands will have manifested a severe
xpression of HCM (e.g., outflow tract obstruction requir-
ng intervention, threatened SCD, a family history of SCD,
r severe symptoms). Asymptomatic (or mildly symptom-
tic) mutation-positive pedigree members tend not to
resent for assessment. Therefore, studies on series of
ndividual probands are subject to even more significant
eferral bias and will overestimate the penetrance and
everity of a gene or given mutation. An ideal study would
omprehensively genotype a large population and systemati-
ally assess its phenotype longitudinally (36); that would avoid
ias. However, the magnitude of this endeavor makes it
nrealistic. A compromise would use probands to identify
edigrees, but after comprehensive cascade genotyping would
xclude the index case from analysis, because the proband’s
henotype tends to overestimate disease severity (37).
The recognition that members of some HCM pedigrees
ere at increased risk of symptoms or SCD led to the
ecognition that individual mutations were associated with
ifferent prognoses (38). Thereafter, certain MHC muta-
ions were nominated as malignant: R403Q, R453C,
716R, R719W. Mutations in troponin T, accounting for
5% to 10% of HCM cases, are characterized by rela-
ively mild and sometimes subclinical LVH but a high
ncidence of SCD (39). In contrast, other missense muta-
ions in MHC (N232S, G256E, F513C, V606M, R719Q,
nd L908V) and the troponin T S179F mutation were
esignated as benign. Even though specific mutations may
e convincingly associated with a malignant or benign
utlook, this should not be misinterpreted to imply that
hose variants will be found at an appreciable rate in patients
ith those clinical characteristics (all mutations are individ-
ally rare and there will be very large numbers of malignant
nd benign examples). Importantly, many studies indicate
hat there are many individual exceptions to such genotype-
henotype predictions, and that genotype is only one
actor among many that determines individual outcomes
36,38,39). In addition, the coinheritance of compound
utations (more than 1 mutation in an individual HCM
ene, or mutations in 2 HCM genes) is more common than
ight be expected and can explain why different families shat appear to have the same mutation can behave differ-
ntly (40).
omplex Trait Analysis: Can
odifier Genes Provide Therapeutic Insights?
epresenting any disorder as purely monogenic is an over-
implification; even seemingly simple mendelian disorders
how features that approximate to complex traits caused by
he interactions of multiple genetic and environmental
actors. This explains the inadequacy of existing approaches
o fully explain the variability in cardiomyopathy pheno-
ypes. Conversely, the offspring of patients with heart failure
ave a 2-fold increase in risk of ventricular systolic dysfunc-
ion; this association may be explained by the aggregation of
enetically transmitted risk factors, such as hypertension
nd diabetes, and/or acquired factors that persist within
amilies, such as culture and diet (41). Additionally, this
amilial predisposition raises the possibility that heart failure
s a complex genetic trait that is in part determined by
nidentified genetic influences. Linkage is often inadequate
o detect such effects. Even if a locus has a moderately large
henotypic effect, linkage analysis is unlikely to be success-
ul, even with large family datasets (3,000 sib-pairs).
herefore, common alleles with a modest contribution to
rait variance are best detected by association methods (42).
he most common form of association study compares the
requency of sequence variants, e.g. SNPs, in a case-control
tudy. A variant (allele) is said to be associated with the
isease if it is overrepresented in case compared with control
ubjects.
enome-wide association studies. A population acts as a
arge outbred pedigree with innumerable crosses; multiple
eiotic recombination events have taken place, and there-
ore genetic markers that continue to be linked with a
utation are those that are in close physical proximity and
n “linkage disequilibrium.” It is now recognized that the
uman genome (3.3 billion base-pairs) consists of 20,000 to
5,000 genes. More than 99.9% of the genome is conserved,
nd the remaining genome that constitutes the differences
etween individual human beings principally (90%) com-
rises SNPs. Single-nucleotide polymorphisms are muta-
ions occurring at single bases and may occur within or
utside sequences coding for proteins or regulating their
xpression. In total, 7 million SNPs with a frequency of
5% exist, of which an assorted 3 million are passed on by
parent to an offspring. The human genome is not
omogeneous but, according to population, comprises “hap-
otype” blocks of conserved DNA containing linked SNPs
hat are inherited en masse. By identifying a single or a few
NPs, the whole block can be deduced. Rapid automated
rray techniques can compare the frequency of such
tagging” SNPs (500,000 distributed across the ge-
ome) between case and control subjects to systematically
earch for variants that contribute to the phenotype. Al-
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Genomics of Cardiomyopathy March 27, 2007:1251–64hough this approach has been used in coronary disease, it
as yet to be exploited in cardiomyopathies.
andidate gene studies. Candidate gene studies are in
rinciple similar to genome-wide association studies, in that
hey compare the frequency of gene variants in case and
ontrol subjects. However instead of systematic studies
cross the whole genome, they concentrate their genetic
ower on a small number of SNPs that are suspected to be
ertinent. They theoretically require fewer patients but are
imited by the requirement for prior knowledge about
isease pathogenesis to select gene variants. Although it has
een reasonable to ascribe the HCM phenotype and prog-
osis principally to sarcomeric mutations, it is clear that
here is extensive phenotypic variability in HCM not
xplained by single-gene defects. For example, in a large
cottish family with TNNT2-mutant HCM, 8 members
ied suddenly aged 30 years and 8 affected members
urvived into old age (39). The environment (e.g., hyper-
ension) and modifier genes are therefore presumed to have
significant influence on HCM. Attempts to identify
odifier genes in cardiomyopathy are therefore attractive,
ot least because modifier effects that protect mutation
arriers from the disease phenotype may be an attractive
arget for intervention.
There are, however, many difficulties with candidate gene
tudies, some of which are generic and others relating
pecifically to aspects of cardiomyopathy. As many as 70%
o 95% of association studies in cardiovascular disease fail to
e confirmed, perhaps exacerbated by publication bias fa-
oring an initial positive result (43). It is important to
educe spurious noise by investigating large, homogeneous,
ell phenotyped populations with carefully matched con-
rols and to limit multiple hypothesis testing. Association
tudies may be confounded by ethnic stratification of the
tudy population, requiring more sophisticated techniques
or their resolution (42). Unfortunately, studies in HCM or
CM tend to be small and the populations heterogeneous.
or example, modifier effects may differ with different
nderlying cardiomyopathy disease gene, or even mutations.
ne attractive study design for dealing with this is to
nalyze large founder effect families where all affected
ubjects share the same exact mutation. End points for
odifier effects are also difficult to define and quantify;
ariation in hypertrophy in HCM in particular is not easily
aptured by any single, normally distributed, continuous
ariable. For example, maximum wall thickness and esti-
ated cardiac mass will yield quite different findings in the
ame family.
Published association studies to test putative modifiers in
ardiomyopathy need to be interpreted against this back-
round. The angiotensin-converting enzyme (ACE) inser-
ion/deletion (I/D) polymorphism has been tested in HCM
n several studies. It may be reasoned that because the DD
enotype is associated with greater plasma ACE concentra-
ions it would be associated with greater disease severity. A
ecent study concluded that polymorphisms in renin- wngiotensin-aldosterone system (RAAS) genes influence
egree of LVH in 26 gene carriers from 1 family with an
YBPC3-HCM mutation (44). Similar studies have also
een attempted in DCM, e.g., to evaluate functional vari-
nts in the 1-, 2-, and 3-adrenergic receptor genes. A
umber of studies of varying size and quality have pursued
his hypothesis and have again produced contrasting and
nconsistent results with respect to both the direction and
he magnitude of effect. Similar conclusions were drawn
bout RAAS polymorphisms (45) and those in adenosine
onophosphate deaminase (AMPD-1) gene (46).
In conclusion, although the associations described are bio-
ogically plausible (inevitable, given the selection of the gene
andidates), study design limitations so far preclude any lasting
onclusions from being made. Genome-wide studies, with
etter study designs, have the potential to raise the reputa-
ion of association studies and potentially provide novel
echanistic and therapeutic insights. However, at present it
emains unknown if adequate power can be achieved with
he study sizes likely to be achievable in relatively uncom-
on disorders such as the cardiomyopathies. While human
enetics struggles with these limitations, perhaps greater
otential exists in systematic mapping strategies for modifier
enes in rodent models of cardiomyopathy. Such ap-
roaches may have different limitations (chiefly, applicabil-
ty to humans) but are at least tractable (47).
enomics of Cardiomyopathies:
he Culmination of New Taxonomy?
n addition to the contribution of genetics to the reclassi-
cation of cardiomyopathies (4) and the mechanistic inter-
st in the genetics underlying HCM/DCM, there is an
spiration that these studies will also reveal the mysteries of
VH, ventricular remodeling, dilation, and decompensation
hat result in heart failure. Although the concept of subtle
ariants in HCM/DCM genes combining to make small
ut cumulatively discernable contributions to common dis-
ases is attractive (32), this appears to be unlikely. Using
hese “pure” diseases to dissect out mechanisms and patho-
ogic pathways underlying common disease seems more
lausible.
Although the expression patterns of many of the 20,000
o 25,000 genes of the genome are pertinent to disease
rogression, they are not captured by conventional genetic
pproaches that concentrate their power on small numbers
f influential genes. An ideal assay would integrate the
omplex dynamic combination of genetic, epistatic, envi-
onmental, and epigenetic factors that, through modifica-
ion of the cellular transcriptome, determine phenotype.
NA or RNA microarrays use “chips” to sample a large
roportion of a cell’s mRNA transcriptome and to provide a
napshot view of gene expression (1). Arrays can be applied to
he powerful study design of comparing 2 related biologic
roups to identify differential gene expression. Once combined
ith complex analytic tools, including clustering algorithms
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March 27, 2007:1251–64 Genomics of Cardiomyopathyhat identify genes that appear to be coregulated, arrays can
dentify transcriptional networks that are pertinent and
ndeed proximate to disease. Not only is this quantitative
nd qualitative dataset informative from a mechanistic
erspective, but it can also identify transcriptional programs
“fingerprints”) amenable to therapeutic intervention and
rognostically subclassify otherwise conventionally indivisi-
le disease states (1).
Significant methodologic limitations remain. 1) The
ltimate mediators of disease are not mRNA but their
erived proteins; the transcriptome is not a perfect surrogate
or the proteome with its added post-translational and
ompartmentalized complexity. Analysis of the transcrip-
ome may fail to reveal the complexities of disease pathways.
) Although the details of the array’s RNA signal analysis is
eyond the scope of the present review, different laborato-
ies use diverse approaches to “clean” their dataset. To
nsure that the data from different laboratories is standard-
zed, standards such as the “minimal information about a
icroarray experiment” have been established (48,49).
) The power of arrays comes at a statistical price; perform-
ng multiple tests (e.g., 10,000 tests per chip) will inevitably
esult in many false positives. Traditional techniques of
djusting for multiple testing (e.g., Bonferroni adjustment)
re not wholly appropriate in this context; novel statistical
echniques are required to reduce false positives while not
uling out pertinent genes. 4) Technical issues notwith-
tanding, the success of any array study is limited by the
uality of biologic samples employed. Improvements in the
eproducibility of commercial chips has shifted the emphasis
way from the chip per se to the biology of the samples. It
s essential that the sample of interest and the control
amples be large enough in number and phenotyped suffi-
iently carefully with respect to the timing and state of the
rganism’s, organ’s, or cell’s life cycle to be comparable and
eproducible (50). 5) Array findings must be subject to
ssessment with independent techniques such as real-time
olymerase chain reaction (PCR) that confirm differences in
NA expression. Some contend that even real-time PCR
ay not suffice and that more sophisticated pathway anal-
sis may be necessary (49). And 6) associations should be
echanistically confirmed in animal models and human
isease to confirm their true biologic relevance.
o functional studies in cardiomyopathies reveal mech-
nistic insights? Although HCM, DCM, and RCM have
raditionally been considered distinct disorders, the identi-
cation of mutations in the same sarcomeric genes in HCM
nd DCM indicates that there may be common themes
nderlying these disorders. Two formal possibilities exist:
) Different mutations in the same sarcomeric genes causing
CM or DCM trigger the same pathway to different
egrees, resulting in a phenotype continuum ranging from
VH to dilatation; or 2) these different mutations activate
istinct programs that remodel the heart differently.
Although it is plausible that mutations causing differingmounts of mutant protein incorporation (51) or differently iutated domains of the same protein could cause graded
henotypes, the experimental data support the distinct-
rogram hypothesis. First, the histology characterizing
CM (i.e., myofiber disarray) is absent in DCM caused by
arcomeric mutations. Second, in vitro assays show that
CM and HCM mutations behave very differently. The
CM mutations depress myofibrillar function, whereas
CM-causing thin filament mutations enhance function
26,52). Specifically, the interrogation of 5 troponin T
utants, 2 -tropomyosin mutants, and 1 troponin C
utant, all known to cause DCM, using in vitro ATPase,
otility, and isometric tension generation assays demon-
trates that, in contrast to HCM mutations, DCM mutants
ause reduced Ca2 sensitivity and reduced thin filament
ctivation (26). The HCM and DCM mutations accord-
ngly cause “distinct programmes.” Nevertheless, 5% of
CM patients undergo dilatation characteristic of DCM
53), and mice bearing a truncation allele of MYBPC3 show
VH in heterozygotes but DCM in homozygotes (54).
ow can this apparent gradedness be reconciled with the
istinct-program hypothesis?
Apoptosis represents a critical pathway in the progression
f heart failure, with myocyte attrition resulting in the
emodeling characteristic of DCM (55). Apoptosis rates
pproach 0.08% to 0.25% of cells in patients with DCM
ompared with 0.001% to 0.002% in control subjects (56).
roapoptogenic animal models demonstrate that apoptosis
ontributes to cardiomyopathy; caspase inhibition prevents
ardiac dilatation and improves left ventricular function
57). Although there is no biophysical relationship between
CM and HCM mutations that dilate, it is likely that
CM mutations stress myocytes more severely and trigger
poptosis (Fig. 2). In contrast, HCM myocytes “compen-
ate” through hypertrophy; apoptosis is less prominent until
ecompensation supervenes. The similarity of the ultimate
henotype of dilated HCM to DCM thus results from late
ellular rather than primary biophysical changes.
o genomic studies in cardiomyopathies confirm and
eveal mechanistic insights? The proposed role for apo-
tosis in HCM and DCM has been supported by a number
f transgenic animal models, including the Gq model of
VH in mice. Moderate levels of Gq signaling induce
VH; more profound Gq activation results in myocyte
poptosis and DCM (57). That sequence of events was
onfirmed with array technology in differing rat models of
athologic LVH and RVH; the transition between hyper-
rophy and dilatation corresponded to the activation of
poptosis (58,59). Genomic studies in animals are thus
onsistent with the hypothesis that DCM is a nonspecific
henotype, with severely stressed myocardium approaching
“burnt-out” proapoptotic state where the rate of apoptosis
xceeds cardiac compensation. In contrast, LVH represents
more complex state, where compensation occurs through
ncreases in cell size and, probably, number.
Human genomic studies have so far proved to be lessnformative. Methodologic challenges are posed by compar-
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Genomics of Cardiomyopathy March 27, 2007:1251–64ng genomic snapshots derived from differing parts of the
eart and from patients at different stages of heart failure
ith varying therapeutic regimens (ranging from medical
herapy to left ventricular assist device [LVAD]-rescued
earts). Patient samples often differ with respect to age,
ender, and ethnicity. Further, the choice of controls may be
imited (60). These heterogeneities, sometimes coupled
Figure 2 The Mechanisms Through Which Cardiac
Stresses Incite Ventricular Dilatation Dysfunction
Diverse cardiac stresses, either through direct toxicity to myocytes or through
processes such as inflammation and/or aberrant calcium dynamics, result in
myocyte apoptosis. The heart initially instigates compensatory responses
according to the nature and severity of the inciting influence. If energy defi-
ciency is a prominent feature of the inciting stress, then hypertrophy may ini-
tially ensue. If compensatory adaptation through hypertrophy and perhaps stem
cell recruitment is inadequate, unchallenged apoptosis will result in myocyte
depletion and myocardial decompensation. The resulting low cardiac output
state promotes an initially adaptive but a chronically maladaptive neurohor-
monal state that perpetuates myocyte apoptosis. This common maladaptive
chronic heart failure state is, at least in part, independent of the proximate inciting
influence and is characterized by neurohormonal activation, metabolic impair-
ment, and maladaptive cardiac remodeling that results in dilated-hypokinetic
ventricles. ACE-I  angiotensin-converting enzyme inhibition; DCM  dilated
cardiomyopathy; HCM  hypertrophic cardiomyopahy.ith small patient numbers, and the technical limitations elready described limit the robustness of human datasets.
evertheless, without resorting to the intuitively appealing
oncept of serial myocardial sampling of a homogeneous
elf-controlled cohort of patients (61), a number of inves-
igators have succeeded in identifying transcriptomes char-
cteristic of distinct cardiomyopathies (62). Although those
ndings contribute phenomenologically to the new taxon-
my of cardiomyopathies and may also discern mechanistic
athways, it cannot be overemphasized that they represent
tatistical association, not causation. The latter proviso was
ecently exemplified by a comparison between failing and
VAD-rescued hearts. LVADs have, in some cases, in-
uced regression of cardiac dysfunction (63). However,
imilar transcriptomes have been identified in both the
ailing and LVAD-unloaded hearts. To have assumed that
he heart failure transcriptome was causative of only the
ilated state would have been erroneous and potentially
isleading (64).
Notwithstanding these methodologic provisos, human
tudies have confirmed the distinct nature of HCM and
CM (65). They have also identified a proapoptotic shift in
umor necrosis factor- signaling as a potential target for
he transition from LVH to decompensated dilatation (66).
enomic profiling has supported genetic taxonomic studies
y distinguishing between different forms of cardiomyopa-
hy, including DCM (67), ischemic (68), alcohol (69),
CM (65), and Chagas’ disease (70) cardiomyopathy.
lthough by their very nature a comprehensive list of
enomic changes would be lengthy, altered energy metab-
lism appears to be one of the most consistent features of
ifferent cardiomyopathies (60). These include changes in
itochondrial, glycolytic, and lipolytic transcriptional pro-
les (60). Recently, a careful genomic comparison of 2
ransgenic mouse models of HCM that express different
utations in the same gene (-tropomyosin) confirms that
nergetics appears to be a key phenotypic determinant of
CM (71). Contemporaneous molecular studies have con-
rmed the role of energy compromise due to excessive ATP
onsumption in HCM (72). Even genomic studies compar-
ng heart transplant recipients with patients suffering from
rypanosoma cruzi cardiac infection, suggest that energetic
isease is a proximate cause for heart failure (73).
enomics of Cardiomyopathies:
mplications for New Therapies?
herapies for cardiomyopathies have been based on mor-
hologic similarities with the more common acquired heart
uscle diseases. This approach has been successful partly
ecause of the nonspecific nature of existing medical ther-
pies and partly because of the limited physiologic repertoire
f responses to cardiac stresses. Nowhere is this more
vident than in DCM. Transcriptome analyses have sup-
orted the view that a dilated ventricle represents a common
burnt-out” phenotype from almost any cardiac insult severe
nough to preclude compensation; the resulting chronic
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March 27, 2007:1251–64 Genomics of Cardiomyopathyeart failure state has been regarded as independent of
nciting etiology and much more a reflection of detrimental
ystemic neurohormonal activation (74). In DCM this has
een supported by consistent measurements of neurohor-
ones and vindicated by the corresponding success of
reatments such as ACE inhibition, beta-blockers, and
ardiac resynchronization therapy. Even in DCM, however,
he variability recognized in transcriptome analyses between
lcoholic, ischemic, and inherited cardiomyopathies has
eawakened interest in a tailored approach to novel thera-
ies. The recognition that metabolic changes represent a
ritical feature of DCM and that glucose metabolism is
own-regulated and fatty acid metabolism is up-regulated
75) has led authors to propose therapeutic agents “which
hift myocardial cells from fatty acid to glucose metabolism”
76). Metabolic modifiers are being actively investigated in
CM; a recent study demonstrated that perhexiline, a
arnitine palmitoyltransferase-1 inhibitor, through aug-
enting glucose and blocking fatty acid metabolism, re-
ulted in unprecedented changes in cardiac function (77).
his approach was successful in both ischemic heart
ailure and inherited DCM, underscoring similarities
n final common path. Based on array studies, similar
rocesses of energy deficiency may also be pivotal in
hagas’ and transplant cardiomyopathy (70,73).
Consistent with the more specific genetics and transcrip-
ome of HCM, it has proved to be more challenging to draw
herapeutic parallels between genetic and acquired variants
f LVH (e.g., HCM vs. hypertensive LVH). There is little
vidence to suggest that RAAS blockade has any role in
CM. Moreover, treatments successfully applied to HCM,
uch as cardioverter-defibrillator implantation to prevent
CD, beta-blockers, and septal ablation, do not treat the
nderlying disease (78). Even therapeutic modalities based
n disease physiology are often only minimally successful.
ual-chamber pacing has been reported to reduce left
entricular outflow tract gradients, but although pacing
ppears to be relatively successful in controlling symptoms
n selected patients (79) randomized trials do not support a
ajor role for pacemaker implantation (80). Transcriptome
nalysis has the capacity to guide therapy; there is extensive
vidence that metabolism also plays a role in the different
orms of LVH. Evidence from array analyses indicates that
he distinction between physiologic and pathologic hyper-
rophy includes differences in glucose and fatty acid metab-
lism (81); this provides a potential new metabolic thera-
eutic node in cardiac hypertrophy.
As noted in the foregoing, HCM represents a prototyp-
cal disease. Insights from genetics, biophysical studies, and
enomic analyses have been combined with careful clinical
henotyping and proof-of-principle physiologic studies to
mplicate a causative rather than a correlative association
etween compromised energetics and HCM. Trials are
nderway to assess the capacity of myocardial metabolism to
odify HCM progression. If disease-modifying treatment
oes become available it is likely to be more effective in farly, perhaps preclinical, disease. In that situation, system-
tic genetic analysis and cascade screening for identification
f HCM-gene carriers will be mandated, with at last a real
hance to reduce HCM morbidity and mortality.
enomics of Cardiomyopathies: The Future?
here is good reason to be optimistic about the continuing
nfluence of new genetic findings on our understanding of
ardiomyopathies. Even very rare mendelian disorders can
eveal new insights with far-reaching consequences, and the
ardiomyopathy disease genes remaining to be discovered
re likely to be in unexpected genes, implicating new
athways. Progress in identification of susceptibility genes
nd modifier genes should follow improvements in auto-
ated technology and growing experience with complex
ata sets, including genome-wide association studies. Sim-
larly, great optimism pertains to further developments in
unctional genomics. Genomic tools will have the capacity
o systematically and rapidly screen a global genomic rep-
rtoire, e.g., of transcripts, proteins, or metabolites, and to
arshal findings using cluster analysis. However, these tools
re simply descriptors without the power of genetics (based
n the principles of cosegregation) to determine causality.
he combined power of both genetic and genomic ap-
roaches is therefore attractive as illustrated by the early
rogress with “genetic genomics.” In that approach, mea-
urements from genomic analyses (e.g., transcript levels) are
nalyzed genetically as quantitative traits. In this way, causal
ssociations between gene variation, gene expression, and
isease are defined.
The recognition that the human genome contains as few
s 20,000 to 25,000 genes has been surprising. This surprise
as been reconciled by the appreciation that much of the
omplexity of our physiology is determined not by large
ifferences in our genetic hardware, but by how complex
ranscriptional programs, guided by transcriptional master-
witches (genetic software), manipulate the smaller gene
epertoire. Thus, phenotypes are determined by transcrip-
ional profiles. Genes that are expressed as part of a
aster-program may be determined by adjacent variants on
he same stretch of DNA (cis regulation) or by signals from
emote regions (trans variants). The patterns and magnitude
f these expression patterns are variable among individuals
thus forming “intermediate phenotypes”). That variability,
n turn, is attributable to inherited influences (polymor-
hisms that act as “expression quantitative trait loci”) in
aster-switches. Taking these factors into account, it is
ossible to identify which loci are implicated and the extent
f their contribution to disease expression through linkage
tudies (82) (Fig. 3). Genetic genomics provides the oppor-
unity to triangulate onto these master-switches and there-
ore to identify the ultimate determinants of complex traits.
he loci determined by these studies can then be corrobo-
ated by mapping of traditional phenotypic traits and by
unctional studies. This has already been achieved in murine
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Genomics of Cardiomyopathy March 27, 2007:1251–64isease models but is some way off in humans. If these
pproaches can be made to work in human populations, and
f (as will be the case for at least some biologic systems)
NA from peripheral blood will be informative (83),
enetics and genomics will together accelerate progress in
uman disease.
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